within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A01A_StomatologicalPreparations.A01AB10_Natamycin;

model Natamycin
  extends Pharmacolibrary.Drugs.ATC.A.A01AB10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A01AB10</td></tr><td>route:</td><td>ocular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Natamycin is a polyene antifungal agent used mainly for the treatment of fungal infections of the eye (such as fungal keratitis, conjunctivitis, and blepharitis) and sometimes for topical treatment of other fungal infections. It is approved and used today primarily as an ophthalmic suspension. Systemic absorption is considered negligible due to its poor solubility and minimal permeability across biological membranes.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or numerical parameter values are available for natamycin in humans; its systemic absorption is considered negligible when administered topically to the eye, and oral bioavailability is extremely low. The following values are general estimates reflecting expected negligible systemic PK after topical ocular administration in adults.</p><h4>References</h4><ol><li><p>Zhao, X, et al., &amp; Lu, H (2018). Comparison of the Ocular Penetration and Pharmacokinetics Between Natamycin and Voriconazole After Topical Instillation in Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 34(6) 460–467. DOI:<a href=&quot;https://doi.org/10.1089/jop.2017.0139&quot;>10.1089/jop.2017.0139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29792548/&quot;>https://pubmed.ncbi.nlm.nih.gov/29792548</a></p></li><li><p>Bhatta, RS, et al., &amp; Shukla, PK (2012). Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. <i>International journal of pharmaceutics</i> 432(1-2) 105–112. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2012.04.060&quot;>10.1016/j.ijpharm.2012.04.060</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22569234/&quot;>https://pubmed.ncbi.nlm.nih.gov/22569234</a></p></li><li><p>Datta, D, et al., &amp; Vora, LK (2024). Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics. <i>International journal of pharmaceutics</i> 658 124192–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2024.124192&quot;>10.1016/j.ijpharm.2024.124192</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38703931/&quot;>https://pubmed.ncbi.nlm.nih.gov/38703931</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Natamycin;
